IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 317 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2016. The put-call ratio across all filers is 1.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,095,964 | +37.7% | 244,620 | +24.6% | 0.01% | +33.3% |
Q2 2023 | $8,056,117 | -24.8% | 196,347 | -34.5% | 0.01% | -14.3% |
Q1 2023 | $10,706,739 | +119.5% | 299,573 | +132.0% | 0.01% | +75.0% |
Q4 2022 | $4,877,202 | -53.4% | 129,129 | -45.5% | 0.00% | -50.0% |
Q3 2022 | $10,477,000 | +89.8% | 236,892 | +58.8% | 0.01% | +100.0% |
Q2 2022 | $5,520,000 | +83.2% | 149,131 | +83.4% | 0.00% | +100.0% |
Q1 2022 | $3,013,000 | -46.8% | 81,336 | -56.3% | 0.00% | -33.3% |
Q4 2021 | $5,661,000 | +39.4% | 186,047 | +53.7% | 0.00% | +50.0% |
Q3 2021 | $4,060,000 | -58.0% | 121,064 | -50.0% | 0.00% | -66.7% |
Q2 2021 | $9,659,000 | -8.6% | 242,123 | +3.0% | 0.01% | -14.3% |
Q1 2021 | $10,568,000 | -31.3% | 235,020 | -13.6% | 0.01% | -30.0% |
Q4 2020 | $15,385,000 | +58.2% | 272,128 | +32.8% | 0.01% | +66.7% |
Q3 2020 | $9,722,000 | -22.9% | 204,908 | -4.1% | 0.01% | -40.0% |
Q2 2020 | $12,604,000 | +33.7% | 213,760 | +7.2% | 0.01% | +25.0% |
Q1 2020 | $9,425,000 | -44.1% | 199,338 | -28.6% | 0.01% | -33.3% |
Q4 2019 | $16,865,000 | +5.3% | 279,186 | +4.4% | 0.01% | -7.7% |
Q3 2019 | $16,016,000 | +3.4% | 267,331 | +10.9% | 0.01% | +8.3% |
Q2 2019 | $15,488,000 | -0.6% | 240,978 | +25.5% | 0.01% | -20.0% |
Q1 2019 | $15,589,000 | -1.2% | 192,042 | -34.2% | 0.02% | -6.2% |
Q4 2018 | $15,775,000 | +93.0% | 291,787 | +84.2% | 0.02% | +100.0% |
Q3 2018 | $8,172,000 | +19.8% | 158,419 | -3.3% | 0.01% | +33.3% |
Q2 2018 | $6,824,000 | +5.5% | 163,747 | +11.6% | 0.01% | +20.0% |
Q1 2018 | $6,468,000 | -33.8% | 146,728 | -24.5% | 0.01% | -28.6% |
Q4 2017 | $9,770,000 | -15.9% | 194,243 | -15.2% | 0.01% | -30.0% |
Q3 2017 | $11,616,000 | -6.4% | 229,083 | -6.1% | 0.01% | -9.1% |
Q2 2017 | $12,416,000 | +70.3% | 244,061 | +34.6% | 0.01% | +57.1% |
Q1 2017 | $7,290,000 | -43.8% | 181,344 | -33.1% | 0.01% | -41.7% |
Q4 2016 | $12,969,000 | +44.2% | 271,111 | +10.5% | 0.01% | +50.0% |
Q3 2016 | $8,991,000 | +100.4% | 245,416 | +27.4% | 0.01% | +60.0% |
Q2 2016 | $4,486,000 | -25.1% | 192,613 | +30.2% | 0.01% | -28.6% |
Q1 2016 | $5,990,000 | -37.6% | 147,894 | -4.6% | 0.01% | -30.0% |
Q4 2015 | $9,600,000 | – | 155,020 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |